Axsome Therapeutics
AXSM
279 hedge funds and large institutions have $3.47B invested in Axsome Therapeutics in 2024 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 84 increasing their positions, 95 reducing their positions, and 22 closing their positions.
109% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 22
9% more funds holding
Funds holding: 257 → 279 (+22)
6% more capital invested
Capital invested by funds: $3.28B → $3.47B (+$197M)
2% more call options, than puts
Call options by funds: $95.7M | Put options by funds: $94M
5.21% less ownership
Funds ownership: 85.79% → 80.58% (-5.2%)
12% less repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 95
27% less funds holding in top 10
Funds holding in top 10: 11 → 8 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$28.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.1M |
| 3 |
ITP
Iron Triangle Partners
Cos Cob,
Connecticut
|
+$22M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.2M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$13.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$86.9M |
| 2 |
Millennium Management
New York
|
-$62.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$39.2M |
| 4 |
RI
RTW Investments
New York
|
-$38.8M |
| 5 |
VPC
Vestal Point Capital
New York
|
-$24.1M |
AXSM Hedge Fund Activity: Q3 2024 in Review
279 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q3 2024, worth a combined $3.47B — up 6% from $3.28B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new AXSM positions and 22 closed out — a net gain of 24 holders — while 84 added to existing stakes and 95 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $28.3M. The largest seller was Deep Track Capital, cutting an estimated $86.9M.
- 279 institutional investors held Axsome Therapeutics (AXSM) as of Q3 2024, up from 257 in Q2 2024.
- Funds reported $3.47B of Axsome Therapeutics stock for Q3 2024, up 6% quarter-over-quarter.
- 46 funds opened new Axsome Therapeutics positions in Q3 2024 and 22 closed out, a net change of +24 holders.
- The largest Axsome Therapeutics buyer in Q3 2024 was Perceptive Advisors, an estimated $28.3M added.
- The largest Axsome Therapeutics seller in Q3 2024 was Deep Track Capital, an estimated $86.9M sold.
Based on aggregated 13F filings for Q3 2024.